Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense therapy in cancer.

W Pawlak1, J Zolnierek, T Sarosiek

  • 1Department of Oncology, Central Clinical Hospital of Military Medical Academy, Warsaw, Poland.

Cancer Treatment Reviews
|September 28, 2000
PubMed
Summary

Antisense oligodeoxynucleotides show promise for treating blood cancers and solid tumors. This review covers their mechanisms, pharmacokinetics, toxicities, and clinical potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urban Water Storage Capacity Inferred From Observed Evapotranspiration Recession.

Geophysical research letters·2022
Same author

Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo.

Scientific reports·2020
Same author

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.

European journal of cancer (Oxford, England : 1990)·2018
Same author

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.

Expert opinion on pharmacotherapy·2015
Same author

Insulin and IGFs in renal cancer risk and progression.

Endocrine-related cancer·2015
Same author

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

British journal of cancer·2015

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Antisense oligodeoxynucleotides (ASOs) are short nucleic acid sequences designed to bind to specific messenger RNA (mRNA) molecules.
  • This binding can modulate gene expression, offering a targeted approach to disease treatment.
  • Their application in cancer therapy is an evolving field of research.

Purpose of the Study:

  • To review the current state of laboratory and clinical research on antisense oligodeoxynucleotides (ASOs) for cancer treatment.
  • To elucidate the mechanisms of action, pharmacokinetics, and toxicities associated with ASO therapeutics.
  • To explore the potential clinical applications of ASOs in treating haematological malignancies and solid tumours.

Main Methods:

  • Literature review of preclinical laboratory studies and clinical trials involving ASOs in oncology.
  • Analysis of published data on ASO pharmacokinetics, including absorption, distribution, metabolism, and excretion.
  • Examination of reported toxicities and adverse events from ASO administration in cancer patients.

Main Results:

  • ASOs demonstrate diverse mechanisms of action against cancer cells, including mRNA degradation and modulation of protein translation.
  • Pharmacokinetic profiles vary depending on ASO chemistry and delivery methods, impacting efficacy and duration of action.
  • Clinical studies have shown varying degrees of success, with some ASOs progressing to later-stage trials for specific cancers.

Conclusions:

  • Antisense oligodeoxynucleotides represent a promising therapeutic strategy for both haematological malignancies and solid tumours.
  • Further research is needed to optimize ASO delivery, enhance efficacy, and manage potential toxicities for broader clinical adoption.
  • The targeted nature of ASOs offers potential for personalized cancer medicine.

Related Experiment Videos